Over 20 years ago, Terol et al. observed that lower expression of ICAM1 in aggressive B-NHL correlates with a more advanced stage of the disease, higher bone marrow infiltration, and worse prognosis [60], however, Schniederjan et al. demonstrated a decreased ICAM1 expression in aggressive BL compared to DLBCL [61]. This evidence concerns the gene ICAM1 and Burkitt lymphoma.